LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Proteomics-Based Diagnostic Test Predicts Risk of Dying from Staphylococcus aureus Bacteremia

By LabMedica International staff writers
Posted on 14 Sep 2020
Image: Using advanced biochemical analysis of patient serum, researchers found signatures that help predict which patients are at highest risk of dying from S. aureus bacteremia, a blood infection (Photo courtesy of University of California, San Diego)
Image: Using advanced biochemical analysis of patient serum, researchers found signatures that help predict which patients are at highest risk of dying from S. aureus bacteremia, a blood infection (Photo courtesy of University of California, San Diego)
A diagnostic approach that integrates proteomic and metabolomic techniques enabled the identification of biomarkers that could predict which patients had the highest risk of dying from Staphylococcus aureus bacteremia.

Staphylococcus aureus bacteremia (SaB) causes significant disease in humans, carrying mortality rates of nearly 25%. The ability to rapidly predict SaB patient responses and guide personalized treatment regimens could reduce mortality.

In order to develop this predictive capability, investigators at the University of California, San Diego (USA) utilized mass spectrometry (MS) to analyze more than 10,000 proteins and metabolites present in more than 200 serum samples collected from the blood of patients with SaB.

Results revealed that by integrating proteomic and metabolomic techniques, the investigators could identify more than 10,000 features from serum samples collected upon clinical presentation. The MS results demonstrated a specific pattern of proteins with and without post-translational modifications that differed in the serum of patients who ultimately died of SaB compared to those who did not. The biomarkers most highly associated with death included lower levels of glycosylated fetuin A, unmodified fetuin B, and thyroxine.

With the area under the curve (AUC) higher than 0.95, the biomarkers identified in this study greatly exceeded the predictive capabilities of those previously reported, particularly when used in combination.

"This finding is a leap forward toward a point-of-care predictive tool for bacteremia risk," said senior author Dr. David Gonzalez, assistant professor of medicine at the University of California, San Diego. "It also opens up lots of new basic biological questions about how our immune systems respond to infections. If I wanted to learn all about you, I would just talk to you directly, not your second cousin. Same thing here - we can gain new and important information by directly "asking" the proteins, rather than their genes, and mass spectrometry is currently the best way to do that in an unbiased manner."

The study was published in the September 3, 2020, online edition of the journal Cell.

Related Links:
University of California, San Diego

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
8-Channel Pipette
SAPPHIRE 20–300 µL

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more